Erotikfilm Vip News

nytimes.com

Latest items from this RSS source.

Republicans Toil to Avoid Saying ‘War’ as Iran Conflict Widens

nytimes.comMar 5, 2026

Mission? Hostilities? Don’t call it a war, say G.O.P. lawmakers grappling with the political and legal challenges of the operation in the Middle East.

After Apalachee High School Shooting, a Hunger for Accountability

nytimes.comMar 5, 2026

The country is casting an ever wider net in its search for accountability. Prosecuting parents is yielding results.

Israel Pushes Farther Into Lebanon, and Readies for More

nytimes.comMar 5, 2026

Days into its offensive against Hezbollah, Israel is massing armored vehicles near the Lebanese border for a potentially much larger ground incursion.

Should New York City Burn Its Parks? This Scientist Thinks So.

nytimes.comMar 5, 2026

An unusual outbreak of wildfires in city parks gave scientists a chance to study these rare events. Now they’re coming to different conclusions.

Sri Lanka Is Caught in the Middle as Second Iranian Vessel Seeks Safe Haven

nytimes.comMar 5, 2026

A day after rescuing Iranian sailors from the wreckage of a warship sunk by a U.S. submarine, Sri Lanka’s neutrality is being tested.

50 Medical Schools Back Kennedy Plan on Nutrition After Pressure

nytimes.comMar 5, 2026

Robert F. Kennedy Jr. announced the commitments in Washington, even as some in the medical community questioned whether the government should try to influence curriculums.

States Sue to Stop Trump From Reviving Steep Tariffs

nytimes.comMar 5, 2026

The lawsuit filed by two dozen attorneys general seeks to invalidate the president’s new, 10 percent global tax on imports.

Senate Democrats Block D.H.S. Funding Again Over Enforcement Guardrails

nytimes.comMar 5, 2026

For the third time, a bill to fund the Department of Homeland Security failed as Democrats refused to support the money without new restrictions on federal immigration agents.

F.D.A. Faces Upset Over Denials of New Drugs

nytimes.comMar 5, 2026

Agency officials promise fast reviews of new treatments while vowing they will not be a “rubber stamp” for the industry. But patients with rare diseases view recent decisions as signs that the doors are closing on their options.